Overview

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Maryland, Baltimore

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Regadenoson